136 related articles for article (PubMed ID: 6183902)
61. Liver damage and methotrexate.
Baker H
Br Med J; 1971 Jun; 2(5764):776. PubMed ID: 5090795
[No Abstract] [Full Text] [Related]
62. Clinical pharmacokinetics of methotrexate.
Shen DD; Azarnoff DL
Clin Pharmacokinet; 1978; 3(1):1-13. PubMed ID: 346283
[No Abstract] [Full Text] [Related]
63. Pontine glioma. High-dose methotrexate and leucovorin rescue.
Rosen G; Ghavimi F; Vanucci R; Deck M; Tan C; Murphy ML
JAMA; 1974 Nov; 230(8):1149-52. PubMed ID: 4547510
[No Abstract] [Full Text] [Related]
64. Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study.
Nyfors A; Jensen H
Dermatologica; 1983; 167(5):260-1. PubMed ID: 6653851
[TBL] [Abstract][Full Text] [Related]
65. Effects of early leucovorin rescue.
Holcenberg JS
J Clin Oncol; 1984 Sep; 2(9):1072. PubMed ID: 6332179
[No Abstract] [Full Text] [Related]
66. Evaluation of methotrexate in the treatment of bronchogenic carcinoma.
Vincent RG; Pickren JW; Fergen TB; Takita H
Cancer; 1975 Sep; 36(3):873-80. PubMed ID: 1182676
[TBL] [Abstract][Full Text] [Related]
67. Commentary and update: methotrexate for psoriasis--two decades later.
Roenigk HH
Cleve Clin Q; 1983; 50(2):107-10. PubMed ID: 6640927
[No Abstract] [Full Text] [Related]
68. Outpatient chemotherapy for breast cancer.
Price LA; Goldie JH
Br Med J; 1977 Dec; 2(6102):1603-4. PubMed ID: 303928
[No Abstract] [Full Text] [Related]
69. The pharmacology of methotrexate.
Olsen EA
J Am Acad Dermatol; 1991 Aug; 25(2 Pt 1):306-18. PubMed ID: 1918470
[TBL] [Abstract][Full Text] [Related]
70. Methotrexate disposition following disruption of the blood-brain barrier.
Markowsky SJ; Zimmerman CL; Tholl D; Soria I; Castillo R
Ther Drug Monit; 1991 Jan; 13(1):24-31. PubMed ID: 2057988
[TBL] [Abstract][Full Text] [Related]
71. Oral methotrexate.
Taylor JR; Halprin KM; Schiff ER
Dig Dis Sci; 1986 Apr; 31(4):443-5. PubMed ID: 3956342
[No Abstract] [Full Text] [Related]
72. Short-term observations in the use of intravenous methotrexate in the treatment of psoriasis.
Land WA
Australas J Dermatol; 1967 Dec; 9(2):183-8. PubMed ID: 5588857
[No Abstract] [Full Text] [Related]
73. Folinic acid rescue and methotrexate toxicity.
Twelves CJ
Lancet; 1986 Mar; 1(8483):737. PubMed ID: 2870242
[No Abstract] [Full Text] [Related]
74. Assay of therapeutic doses of methotrexate in body fluids of patients with psoriasis.
Noble WC; White PM; Baker H
J Invest Dermatol; 1975 Feb; 64(2):69-76. PubMed ID: 1123553
[TBL] [Abstract][Full Text] [Related]
75. Methotrexate dosage in patients aged over 50 with psoriasis.
Fairris GM; Dewhurst AG; White JE; Campbell MJ
BMJ; 1989 Mar; 298(6676):801-2. PubMed ID: 2496860
[No Abstract] [Full Text] [Related]
76. The treatment of psoriasis with parenteral methotrexate.
Fry L
Br J Dermatol; 1966 May; 78(5):282-8. PubMed ID: 5937350
[No Abstract] [Full Text] [Related]
77. [Practical aspects of the cytostatic therapy of psoriasis].
Rassner G
Z Hautkr; 1976 Jun; 51(12):499-506. PubMed ID: 60007
[TBL] [Abstract][Full Text] [Related]
78. Cytokinetics and chemotherapy of psoriasis.
Weinstein GD; McCullough JL
J Invest Dermatol; 1976 Jul; 67(1):26-30. PubMed ID: 778295
[TBL] [Abstract][Full Text] [Related]
79. Desmosomal abnormalities in the liver of methotrexate-treated psoriatics.
Horvath E; Kovacs K; Ross RC; Saibil F; Kerenyi NA
Experientia; 1977 Sep; 33(9):1202-4. PubMed ID: 560985
[TBL] [Abstract][Full Text] [Related]
80. Methotrexate: a calculated risk.
Caron GA
Arch Dermatol; 1969 May; 99(5):627-8. PubMed ID: 5780968
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
